Trial Profile
Non-interventional Study in Allergic Patients Suffering from Grass Pollen Induced Rhinitis/Rhinoconjunctivitis with or without Asthma. Retrospective Assessment of the Efficacy of a Perennial Specific Immunotherapy on the Allergy Symptoms / Disease Activity during the Pollen Season.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Nov 2016
Price :
$35
*
At a glance
- Drugs Grass pollen allergy immunotherapy (Primary)
- Indications Allergic rhinitis; Rhinoconjunctivitis
- Focus Therapeutic Use
- Acronyms Depigoid Phleum-PRO 2013
- Sponsors LETI Pharma GmbH
- 29 Nov 2016 New trial record